DexCom, Inc. (NASDAQ:DXCM) Director Mark G. Foletta sold 1,000 shares of the stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $121.89, for a total value of $121,890.00. Following the transaction, the director now owns 4,052 shares of the company’s stock, valued at $493,898.28. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
DXCM stock traded down $1.37 during mid-day trading on Friday, reaching $118.04. The company had a trading volume of 644,003 shares, compared to its average volume of 1,099,657. The company has a debt-to-equity ratio of 1.57, a current ratio of 7.18 and a quick ratio of 6.75. The firm has a market capitalization of $10.87 billion, a P/E ratio of 393.47 and a beta of 0.73. DexCom, Inc. has a fifty-two week low of $85.76 and a fifty-two week high of $156.16.
DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Wednesday, May 1st. The medical device company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.12. The company had revenue of $280.50 million for the quarter, compared to analyst estimates of $246.10 million. DexCom had a positive return on equity of 8.45% and a negative net margin of 11.51%. DexCom’s revenue for the quarter was up 52.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.30) EPS. On average, analysts expect that DexCom, Inc. will post 0.77 EPS for the current year.
A number of hedge funds have recently bought and sold shares of DXCM. Laurel Wealth Advisors LLC acquired a new stake in DexCom in the 4th quarter valued at about $26,000. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of DexCom during the 4th quarter worth about $33,000. Private Ocean LLC acquired a new stake in shares of DexCom during the 1st quarter worth about $36,000. Kore Private Wealth LLC acquired a new stake in shares of DexCom during the 1st quarter worth about $40,000. Finally, Canton Hathaway LLC acquired a new stake in shares of DexCom during the 1st quarter worth about $41,000. 96.15% of the stock is currently owned by institutional investors.
A number of equities analysts recently commented on DXCM shares. Zacks Investment Research upgraded DexCom from a “hold” rating to a “buy” rating and set a $138.00 target price for the company in a report on Monday, May 6th. ValuEngine cut DexCom from a “strong-buy” rating to a “buy” rating in a report on Monday, April 1st. Canaccord Genuity raised their target price on DexCom from $140.00 to $160.00 and gave the company a “buy” rating in a report on Friday, February 22nd. TheStreet cut DexCom from a “c” rating to a “d+” rating in a report on Friday, April 5th. Finally, Morgan Stanley raised their target price on DexCom from $135.00 to $160.00 and gave the company an “equal weight” rating in a report on Monday, February 25th. Five investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $152.25.
ILLEGAL ACTIVITY NOTICE: “Mark G. Foletta Sells 1,000 Shares of DexCom, Inc. (DXCM) Stock” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.dispatchtribunal.com/2019/05/18/mark-g-foletta-sells-1000-shares-of-dexcom-inc-dxcm-stock.html.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Featured Story: Investing in Growth Stocks
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.